8-K: NeOnc Secures $1M, NEO100 Shows Enhanced Brain Tumor Efficacy

NeOnc Technologies Holdings, Inc. announced a $1 million private placement of common stock and positive preclinical findings for its NEO100 therapeutic in combination with ultrasound for brain tumors.

Summary

• NeOnc Technologies Holdings, Inc. (the Company) entered into a Securities Purchase Agreement on December 1, 2025, with Saad Naja (the Investor).
• The Company agreed to issue and sell 111,732 shares of its common stock at a per share price of $8.95, which was the closing price on the Nasdaq Capital Market on November 28, 2025.
• The total proceeds from this sale amounted to approximately $1 million.
• The Company intends to use the net proceeds from this offering for working capital.
• The shares were issued under an exemption from registration requirements provided in Section 4(a)(2) of the Securities Act of 1933.
• The Company committed to filing a resale registration statement for these shares no later than ten (10) days after the date of the Agreement.
• On December 1, 2025, the Company also issued a press release announcing new preclinical findings from a research collaboration at the University of Southern California (USC).
• The study demonstrated that focused ultrasound significantly enhances NEO100's therapeutic potency, driving strong antitumor effects across multiple primary and metastatic brain tumor types.
• An AI-driven, 3D-bioprinted platform identified NEO100 as a leading sonodynamic therapy agent.
• Validation studies on rapidly bioprinted tumor spheroids, including glioblastoma, pediatric medulloblastoma, high-grade meningioma, and breastand lung-to-brain metastases, confirmed enhanced tumor-killing activity when NEO100 was combined with focused ultrasound.

Sentiment

Score: 8

Explanation: The capital raise provides immediate working capital, and the preclinical findings for NEO100, especially with the enhanced potency from ultrasound and the use of AI/3D bioprinting, represent a significant positive development for the company's pipeline and future clinical opportunities. These are strong indicators of progress, though still preclinical.

Positives

• Successfully raised approximately $1 million through a private placement, providing additional working capital for the Company's operations.
• Positive preclinical findings demonstrate that focused ultrasound significantly enhances NEO100's therapeutic potency against a wide range of primary and metastatic brain tumors.
• The use of an AI-driven, 3D-bioprinted platform, built on NTHI-patented technology, accelerates biomedical research and consistently identified NEO100 as a leading sonosensitizer.
• Validation studies confirmed enhanced tumor-killing activity of NEO100 with focused ultrasound across aggressive brain tumor types, including glioblastoma and various metastases.
• The integration of AI, 3D bioprinting, and ultrasound significantly expands NEO100's commercial and clinical opportunities beyond current indications.
• NEO100 and NEO212 therapeutics are already in Phase II human clinical trials and hold FDA Fast-Track and Investigational New Drug (IND) status.

Risks

• The Company's ability to perform its obligations under the Securities Purchase Agreement or consummate the transactions could be materially adversely affected by changes in its business, financial condition, results of operations, shareholders' equity, properties, or prospects.
• There is a risk of non-compliance with applicable statutes, rules, regulations, orders, or restrictions that could materially and adversely affect the Company's business, assets, liabilities, financial condition, or operations.
• The Company faces potential litigation, regulatory actions, or investigations that could have a Material Adverse Effect.
• The SEC may limit the number of shares that can be included in the resale registration statement, requiring the Company to undertake additional registration efforts for any excluded shares.
• Forward-looking statements are subject to risks and uncertainties, including the failure to finalize agreements, modifications to terms, or alternative uses of proceeds, as detailed in the Company's Form 10-K.

Future Outlook

The positive preclinical findings for NEO100 combined with focused ultrasound support moving this therapeutic approach into future clinical trials for a wide range of primary and metastatic brain tumors. The Company intends to use the net proceeds from the recent stock offering for working capital to support ongoing operations and development.

Management Comments

• "This breakthrough provides strong external validation for NEO100s potential as a first-in-class, noninvasive sonodynamic therapeutic."
• "The integration of AI, 3D bioprinting, and ultrasound significantly expands NEO100s commercial and clinical opportunity beyond current indications." Amir Heshmatpour, Executive Chairman and President of NTHI.

Industry Context

The biopharmaceutical industry, particularly in oncology and CNS disorders, is increasingly leveraging advanced technologies like AI and 3D bioprinting to accelerate drug discovery and development. NeOnc's use of an AI-driven 3D-bioprinted platform for identifying sonodynamic therapy agents and validating NEO100's enhanced potency with ultrasound aligns with this trend, potentially offering a non-invasive treatment modality for challenging brain tumors where current options are limited.

Stakeholder Impact

• Shareholders: The capital raise provides financial stability, and the positive preclinical results for NEO100 could increase investor confidence and potentially future share value, despite minimal dilution from the new share issuance.
• Patients: The advancement of NEO100 with ultrasound offers potential for a new, non-invasive therapeutic option for various primary and metastatic brain tumors, addressing a significant unmet medical need.
• Employees: Continued progress in drug development and financial stability can provide job security and opportunities within the Company.

Next Steps

• File a resale registration statement for the 111,732 shares within 10 days after December 1, 2025.
• Move NEO100 combined with focused ultrasound into future clinical trials for primary and metastatic brain tumors.
• Continue Phase II human clinical trials for NEO100 and NEO212.

Key Dates

Recommendation

While the capital raise provides necessary working capital and the preclinical data for NEO100 with ultrasound is very promising, indicating expanded clinical and commercial opportunities, the company remains clinical-stage. The positive findings are preclinical and need to be validated in human clinical trials. The stock is likely to see positive movement on this news, but a 'buy' recommendation would typically await further clinical trial success and clearer path to commercialization. For now, existing investors should hold, and new investors might consider initiating a small position given the long-term potential.

Keywords

NeOnc Technologies, NTHI, NEO100, brain tumors, ultrasound therapy, sonodynamic therapy, AI-driven drug discovery, 3D bioprinting, private placement, common stock, biopharmaceutical, CNS cancers, oncology, glioblastoma, medulloblastoma, meningioma, metastatic brain cancer